Renal function and venous thromboembolic diseases

J Mal Vasc. 2016 Dec;41(6):389-395. doi: 10.1016/j.jmv.2016.09.001. Epub 2016 Oct 28.ABSTRACTAnticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agents in CKD patients because of the pharmacokinetic modifications of these drugs in this population. These modifications may lead to overdosage and dose-related side effects, such as bleeding. It is therefore necessary to screen VTE patients for CKD and to modify the doses of anticoagulants, if necessary.PMID:28029509 | DOI:10.1016/j.jmv.2016.09.001

Source: Journal des Maladies Vasculaires - December 29, 2016 Category: Cardiology Authors: N Janus I Mah é V Launay-Vacher J-P Laroche G Deray Source Type: research